HomeToday’s HighlightsAmgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Today’s Highlights April 10, 2019 Amgen and UDB Granted FDA Approval of Evenity™ Amgen (AMGN) and UCB Pharmaceuticals (This content is for paid subscribers. Please click here to subscribe or here to log in. Today’s Highlights Amgen (AMGN), UCB Pharmaceuticals (UCB) April 10, 2019 Tweet Pin It Other Articles Shoreline Biosciences to Acquire Editas Medicine’s iNK cell franchise January 19, 2023 0 CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics January 5, 2023 1 Why Kala Pharmaceuticals Stock is Soaring December 28, 2022 0 Madrigal Pharmaceuticals and Akero Therapeutics: After Having No Treatment for NASH, We Now Have Two Products Expected to be Approved December 19, 2022 0